Literature DB >> 9236856

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.

S P Henry1, D Monteith, F Bennett, A A Levin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9236856

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN： 0266-9536


× No keyword cloud information.
  9 in total

1.  A cytosine analog that confers enhanced potency to antisense oligonucleotides.

Authors:  W M Flanagan; J J Wolf; P Olson; D Grant; K Y Lin; R W Wagner; M D Matteucci
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.

Authors:  Ranjana Advani; Bert L Lum; George A Fisher; Joanne Halsey; Richard S Geary; Jon T Holmlund; T Jesse Kwoh; F Andrew Dorr; Branimir I Sikic
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

3.  A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma.

Authors:  Xiaoming Yao; Ji-Fan Hu; Mark Daniels; Hadas Shiran; Xiangjun Zhou; Huifan Yan; Hongqi Lu; Zhilan Zeng; Qingxue Wang; Tao Li; Andrew R Hoffman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

4.  Lack of toxicity of a STAT3 decoy oligonucleotide.

Authors:  Malabika Sen; Patricia J Tosca; Christa Zwayer; Michael J Ryan; Jerry D Johnson; Katherine A B Knostman; Patricia C Giclas; James O Peggins; Joseph E Tomaszewski; Timothy P McMurray; Changyou Li; Michael S Leibowitz; Robert L Ferris; William E Gooding; Sufi M Thomas; Daniel E Johnson; Jennifer R Grandis
Journal:  Cancer Chemother Pharmacol       Date:  2008-09-03       Impact factor: 3.333

5.  From the Cover: The Minipig is a Suitable Non-Rodent Model in the Safety Assessment of Single Stranded Oligonucleotides.

Authors:  Annamaria Braendli-Baiocco; Matthias Festag; Kamille Dumong Erichsen; Robert Persson; Michael J Mihatsch; Niels Fisker; Juergen Funk; Susanne Mohr; Rainer Constien; Corinne Ploix; Kevin Brady; Marco Berrera; Bernd Altmann; Barbara Lenz; Mudher Albassam; Georg Schmitt; Thomas Weiser; Franz Schuler; Thomas Singer; Yann Tessier
Journal:  Toxicol Sci       Date:  2017-05-01       Impact factor: 4.849

6.  Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.

Authors:  Moizza Mansoor; Alirio J Melendez
Journal:  Gene Regul Syst Bio       Date:  2008-09-22

7.  In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization.

Authors:  Piotr J Kamola; Jeremy D A Kitson; Gemma Turner; Klio Maratou; Sofie Eriksson; Aliza Panjwani; Linda C Warnock; Gaelle A Douillard Guilloux; Kitty Moores; Emma L Koppe; William E Wixted; Paul A Wilson; Nigel J Gooderham; Timothy W Gant; Kenneth L Clark; Stephen A Hughes; Mark R Edbrooke; Joel D Parry
Journal:  Nucleic Acids Res       Date:  2015-09-03       Impact factor: 16.971

8.  Chemical Modification of CRISPR gRNAs Eliminate type I Interferon Responses in Human Peripheral Blood Mononuclear Cells.

Authors:  Mollie S Schubert; Edward Cedrone; Barry Neun; Mark A Behlke; Marina A Dobrovolskaia
Journal:  J Cytokine Biol       Date:  2018-01-29

9.  Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant.

Authors:  H Zhang; R Hanecak; V Brown-Driver; R Azad; B Conklin; M C Fox; K P Anderson
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.